Corcept Therapeutics (United States)

Corcept Therapeutics is a pharmaceutical company developing treatments for severe metabolic, oncologic, and psychiatric disorders by modulating cortisol activity. Based in Menlo Park, California, Corcept created Korlym (mifepristone), the first FDA-approved treatment for hyperglycemia in Cushing’s syndrome patients. The company’s cortisol modulator research targets endocrine disorders, depression, and cancer.